Artificial Intelligence

Echo AI Improves LVEF Workflow and Variability

Cedars-Sinai researchers published what might be the strongest evidence yet of AI’s ability to improve echocardiography workflows and accuracy.

The researchers randomized 3,495 transthoracic echo LVEF studies to be assessed by either a Cedars-Sinai-developed AI tool or expert sonographers (within the standard cardiology PACS workflow), before final assessments by blinded cardiologists.

This was the first blinded RCT evaluating an echo AI solution, and one of the first for any imaging AI solutions.

Echo AI nailed the study’s primary endpoint, as the final cardiologist assessments required substantial LVEF changes (>5% change) far less often with AI-based studies than those from the sonographer group (16.8% vs. 27.2%).

The echo AI solution AI further supported its advantage over sonographer assessments, producing…

  • A smaller average LVEF difference between the initial and final cardiologist assessments (2.79% vs. 3.77%)
  • A smaller average LVEF difference between the final cardiologist assessments and patients’ previous/historical cardiologist assessments (6.29% vs. 7.23%)
  • Faster average initial LVEF assessments (AI 131 seconds faster)
  • Faster median cardiologist LVEF assessments (54 vs. 64 seconds)

The blinded cardiologists also often couldn’t tell whether AI or the human sonographers produced the initial assessments (43%), while predicting the correct assessment source only slightly more often than the incorrect source (32% & 24%).

The Takeaway

This study shows that AI-based LVEF assessments can be “non-inferior and even superior” to initial assessment by sonographers, while also reducing labor and variability throughout the echo workflow. 

Even though previous echo AI research has produced similar results and this study only used data from a single center, the fact that it was echo AI’s first blinded RCT is very notable, and bolsters the growing body of evidence supporting AI’s ability to improve echo workflows in the real world.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!